CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis

Beijing, China; Burlington, Mass., November 15, 2022— CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials